Loading...
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers
CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities—ie, migration, in...
Saved in:
| Published in: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Impact Journals LLC
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5342505/ https://ncbi.nlm.nih.gov/pubmed/27626701 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11935 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|